| abstract |
(57) Abstract: known peptidic NK 3 receptor antagonists are very unstable metabolic point of view, can not be used as the actual therapeutic agent. SOLUTION: The quinoline derivative of the formula (I) specially described in the present specification is extremely superior in stability from a metabolic point of view as compared with known peptide antagonists, and has convulsive disorders (eg, epilepsy), Renal insufficiency, urinary incontinence, eye inflammation, inflammatory pain, ataxia (inhibition of food intake), allergic rhinitis, neurological diseases (eg, Alzheimer's disease), psoriasis, It can be used to treat Huntington's chorea and depression. |